Lv11
20 积分 2023-02-19 加入
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
4分钟前
待确认
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
35分钟前
已完结
MA12.08 Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
1小时前
已完结
Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial
2个月前
已关闭
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria
5个月前
已完结
Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma
5个月前
已完结
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study
5个月前
已关闭
Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization
6个月前
已完结
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
7个月前
已完结
Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients
7个月前
已完结
皖公网安备34019202002308
